[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563181":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Centre Francois Baclesse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Blood and tumor collection",null,"Blood and tumor collection before treatment initiation",[13],"Other: organoid etablishment",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"organoid etablishment","Prior to initiation of 1st-line therapy:\n\n* Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample)\n* A blood test blood a for tumoroid realization and :\n* Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo\n* Analysis of correlation between in vivo and ex vivo tumor characteristics\n* Analysis of first- and second-line survival rates and overall survival",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"zoé NEVIERE, Medical Doctor","CONTACT","33231455050","z.neviere@baclesse.unicancer.fr",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Centre François Baclesse","RECRUITING","Caen","France","FR",{"type":33,"coordinates":34},"Point",[35,36],-0.35912,49.18585,{"lat":36,"lon":35},[39],{"name":40,"role":22,"phone":23,"phoneExt":10,"email":24},"Zoé NEVIERE, MD",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100563181","development-of-tumor-organoids-from-undifferentiated-primary-carcinomas-to-guide-therapeutic-decisions-100563181",false,"NCT06612827","Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions","OCAPI","Inclusion Criteria:\n\n* Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and\u002For national UPC multidisciplinary consultation\n* Patient with indication for systemic 1st-line treatment at the time of inclusion. Treatment may already have begun at the time of inclusion, but within the limit of 2 treatment cycles administered.\n* Patient with life expectancy greater than 3 months\n* Patient of legal age\n* Patient affiliated to a social security scheme\n* Signature of informed consent prior to any specific study procedure\n\nExclusion Criteria:\n\n* Persons deprived of their liberty or under guardianship (including curatorship)\n* Pregnant or breast-feeding patient","ALL","18 Years",{"count":53,"type":54},20,"ESTIMATED","OBSERVATIONAL","The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.",[58],"Undifferentiated Carcinoma",[60,61],"tumoroid","organoid","2025-12-23",{"date":64,"type":65},"2025-12-24","ACTUAL",{"date":67,"type":65},"2025-03-05",{"date":69,"type":54},"2032-12-15",{"name":5,"class":6},1]